| Hazard Information | Back Directory | [Uses]
Amivantamab (JNJ-61186372) is a human EGFR-MET bispecific antibody with immune anticancer activity. Amivantamab inhibits ligand binding, promotes endocytosis and degradation of receptor-antibody complexes, and induces Fc-dependent cytokinesis in macrophages and antibody-dependent cytotoxicity in natural killer cells[1]. | [in vivo]
Amivantamab (JNJ-61186372)(i.p, 30 mg/kg, twice a week, 15 days)effectively reduces tumour volume in female thymus-free BALB-c/nu mouse xenograft model of NSCLC with EGFR Exon20ins mutation and has in vivo anti-tumour effects[2].
| [storage]
Store at -20°C | [References]
[1] Keunchil Park, et al. Amivantamab in EGFR Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study. J Clin Oncol. 2021 Oct 20;39(30):3391-3402. DOI:10.1200/JCO.21.00662
[2] Jiyeon Yun, et al. Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR-MET Bispecific Antibody, in Diverse Models of?EGFR?Exon 20 Insertion-Driven NSCLC. Cancer Discov. 2020 Aug;10(8):1194-1209. DOI:10.1158/2159-8290.CD-20-0116 |
|
| Company Name: |
Biolab Reagents
|
| Tel: |
027-65279366 18108604356 |
| Website: |
www.biolabreagent.com/ |
| Company Name: |
Cell Sciences
|
| Tel: |
9785721070 |
| Website: |
www.cellsciences.com |
|